Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents.

Palagyi A, Neveling K, Plinninger U, Ziesch A, Targosz BS, Denk GU, Ochs S, Rizzani A, Meier D, Thasler WE, Hanenberg H, De Toni EN, Bassermann F, Schäfer C, Göke B, Schindler D, Gallmeier E.

Mol Cancer. 2010 May 28;9:127. doi: 10.1186/1476-4598-9-127.

2.

Gene-specific selection against experimental fanconi anemia gene inactivation in human cancer.

Gallmeier E, Hucl T, Calhoun ES, Cunningham SC, Bunz F, Brody JR, Kern SE.

Cancer Biol Ther. 2007 May;6(5):654-60. Epub 2007 Feb 7.

PMID:
17387268
3.

The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC.

Taniguchi T, D'Andrea AD.

Blood. 2002 Oct 1;100(7):2457-62.

4.

Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.

Kachnic LA, Li L, Fournier L, Willers H.

Cancer Lett. 2010 Jun 1;292(1):73-9. doi: 10.1016/j.canlet.2009.11.009. Epub 2010 Jan 19.

PMID:
20034732
5.

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.

Gallmeier E, Calhoun ES, Rago C, Brody JR, Cunningham SC, Hucl T, Gorospe M, Kohli M, Lengauer C, Kern SE.

Gastroenterology. 2006 Jun;130(7):2145-54.

PMID:
16762635
6.

Function of the Fanconi anemia pathway in Fanconi anemia complementation group F and D1 cells.

Siddique MA, Nakanishi K, Taniguchi T, Grompe M, D'Andrea AD.

Exp Hematol. 2001 Dec;29(12):1448-55.

PMID:
11750104
7.

Disruption of the FA/BRCA pathway in bladder cancer.

Neveling K, Kalb R, Florl AR, Herterich S, Friedl R, Hoehn H, Hader C, Hartmann FH, Nanda I, Steinlein C, Schmid M, Tonnies H, Hurst CD, Knowles MA, Hanenberg H, Schulz WA, Schindler D.

Cytogenet Genome Res. 2007;118(2-4):166-76.

PMID:
18000367
8.

Functional defects in the fanconi anemia pathway in pancreatic cancer cells.

van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE.

Am J Pathol. 2004 Aug;165(2):651-7.

9.

FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway.

Gordon SM, Alon N, Buchwald M.

J Biol Chem. 2005 Oct 28;280(43):36118-25. Epub 2005 Aug 26.

10.

High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.

Gallmeier E, Hucl T, Brody JR, Dezentje DA, Tahir K, Kasparkova J, Brabec V, Bachman KE, Kern SE.

Cancer Res. 2007 Mar 1;67(5):2169-77.

11.

The Fanconi anemia protein FANCF forms a nuclear complex with FANCA, FANCC and FANCG.

de Winter JP, van der Weel L, de Groot J, Stone S, Waisfisz Q, Arwert F, Scheper RJ, Kruyt FA, Hoatlin ME, Joenje H.

Hum Mol Genet. 2000 Nov 1;9(18):2665-74.

PMID:
11063725
12.

In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.

van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE.

Clin Cancer Res. 2005 Oct 15;11(20):7508-15.

13.
14.

A role for the Fanconi anemia C protein in maintaining the DNA damage-induced G2 checkpoint.

Freie BW, Ciccone SL, Li X, Plett PA, Orschell CM, Srour EF, Hanenberg H, Schindler D, Lee SH, Clapp DW.

J Biol Chem. 2004 Dec 3;279(49):50986-93. Epub 2004 Sep 17.

15.

Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.

Adachi D, Oda T, Yagasaki H, Nakasato K, Taniguchi T, D'Andrea AD, Asano S, Yamashita T.

Hum Mol Genet. 2002 Dec 1;11(25):3125-34.

PMID:
12444097
16.

Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.

Lombardi AJ, Hoskins EE, Foglesong GD, Wikenheiser-Brokamp KA, Wiesmüller L, Hanenberg H, Andreassen PR, Jacobs AJ, Olson SB, Keeble WW, Hays LE, Wells SI.

Clin Cancer Res. 2015 Apr 15;21(8):1962-72. doi: 10.1158/1078-0432.CCR-14-2616. Epub 2015 Jan 21.

17.

Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.

Ferrer M, de Winter JP, Mastenbroek DC, Curiel DT, Gerritsen WR, Giaccone G, Kruyt FA.

Cancer Gene Ther. 2004 Aug;11(8):539-46.

PMID:
15192709
18.

Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.

Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG.

Hum Mol Genet. 2003 Oct 1;12(19):2503-10. Epub 2003 Aug 5.

PMID:
12915460
19.

Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.

Jacquemont C, Simon JA, D'Andrea AD, Taniguchi T.

Mol Cancer. 2012 Apr 26;11:26. doi: 10.1186/1476-4598-11-26.

20.

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.

Ueda F, Sumi K, Tago K, Kasahara T, Funakoshi-Tago M.

Cell Signal. 2013 Nov;25(11):2115-24. doi: 10.1016/j.cellsig.2013.07.003. Epub 2013 Jul 6.

PMID:
23838005

Supplemental Content

Support Center